Post-Authorization Activity Table (PAAT) for Mekinist

The PAAT describes post-authorization activity for Mekinist, a product which contains the medicinal ingredient Trametinib dimethyl sulfoxide. Based on Health Canada's review, the benefit/risk profile of Mekinist is favourable as a monotherapy for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Read more here.